Clinical Trial Update: The Impact of Tredaptive on Flow-Mediated Dilation in Cardiac Patients [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating Tredaptive's effect on flow-mediated dilation in patients with coronary artery disease and dyslipidemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Dyslipidemia

Drugs mentioned

• TREDAPTIVE (niacin/laropiprant)

Snippet

Sponsor: Sheba Medical Center | Conditions: Coronary Artery Disease, Dyslipidemia | Phase 4 | Status: TERMINATED